Table 3.
Univariable and multivariable analyses for the risk factors of survival
| Parameters | OS | EFS | |||||
|---|---|---|---|---|---|---|---|
| Univariable HR (95%CI); P |
Multivariable HR (95%CI); P |
Univariable HR (95%CI); P |
Multivariable HR (95%CI); P |
||||
|
Gender male vs. female |
1.428 (0.772–2.642); 0.257 |
- |
1.405 (0.763–2.588); 0.275 |
- | |||
|
Patient’s age < 35.5 vs. ≥ 35.5 years (median) |
0.925 (0.511–1.675); 0.797 |
- |
0.960 (0.534–1.725); 0.891 |
- | |||
|
Disease status at transplant CRc vs. NR |
0.438 (0.234–0.821); *0.010 |
0.493 (0.244–0.994) *0.048 |
0.449 (0.241–0.839); *0.012 |
0.566 (0.283–1.131); 0.089 |
|||
| Donor type | |||||||
|
HLA-matched sibling vs. HLA-haploidentical related |
0.930 (0.691–1.253); 0.634 |
- |
0.912 (0.680–1.223); 0.539 |
- | |||
| ELN classification# | |||||||
| Adverse | Reference | - | Reference | - | |||
| Intermediate |
0.600 (0.278–1.297); 0.194 |
- |
0.557 (0.257–1.207); 0.138 |
- | |||
| Favorable |
0.427 (0.102–1.780); 0.243 |
- |
0.405 (0.097–1.691); 0.215 |
- | |||
| Relapse type post-transplant | |||||||
| Hematologic | Reference | - | Reference | - | |||
| Extramedullary |
0.257 (0.061–1.072); 0.062 |
0.291 (0.065-1.300); 0.106 |
0.229 (0.055–0.952); *0.043 |
0.287 (0.065–1.269); 0.100 |
|||
| Hematologic + extramedullary |
0.699 (0.292–1.670); 0.420 |
- |
0.716 (0.301–1.705); 0.451 |
- | |||
|
Relapse time post-transplant ≥6 months vs.<6 months |
0.501 (0.274–0.916); *0.025 |
0.778 (0.396–1.532); 0.468 |
0.442 (0.243–0.804); *0.007 |
0.611 (0.313–1.195); 0.150 |
|||
|
Salvage therapy including sorafenib Sorafenib vs. no sorafenib |
0.484 (0.265–0.885); *0.018 |
0.395 (0.209–0.746); *0.004 |
0.511 (0.282–0.925); *0.027 |
0.406 (0.218–0.754); *0.004 |
|||
|
Salvage therapy including DLI DLI vs. no DLI |
0.627 (0.308–1.274); 0.197 |
- |
0.642 (0.317-1.300); 0.218 |
- | |||
|
aGVHD after salvage therapy aGVHD vs. no aGVHD |
0.805 (0.406–1.595); 0.534 |
- |
1.021 (0.527–1.979); 0.950 |
- | |||
|
cGVHD after salvage therapy cGVHD vs. no cGVHD |
0.549 (0.264–1.145); 0.110 |
- |
0.555 (0.267–1.154); 0.115 |
- | |||
Abbreviations: OS, overall survival; EFS, event-free survival; HR, hazard ratios; CI, confidence interval; CRc, composite complete remission; NR, no response; DLI, donor lymphocyte infusion; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; * P<0.05. #referred to 2022 European Leukemia Net risk stratification